Trial intelligence / Profile preview

PK of HIP1403 vs HGP0919 in Healthy Males

NCT02941731Phase 1Completed

Sponsor
Hanmi Pharmaceutical
Start
Apr 2015
Primary completion
Sep 2015
Modality
Small Molecules
Countries
1
01

Overview

Phase 1, randomised, open-label trial of oseltamivir in influenza (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Oseltamivir Cmax, Oseltamivir AUClast and 1 more. Started Apr 2015; status: completed.

02

Drugs

oseltamivir
03

Conditions

influenza

Beyond the preview

Go deeper on NCT02941731.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02941731.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call